Drugs / MP0533
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05673057 | Dec 2022 → May 2026 overdue | leukemia, myeloid neoplasm | Molecular Partners AG | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP0533 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673057 ↗ |
| Action | Deplete | “T cell-mediated killing of AML cells” PMID 38683145 ↗ Jul 2024 |
| Modality | Protein / enzyme biologic | “multispecific CD3-engaging designed ankyrin repeat protein (DARPin)” PMID 38683145 ↗ Jul 2024 |
| Route | Intravenous | “MP0533 is administered by intravenous infusion” NCT05673057 ↗ |
| Target | CD123 | “can simultaneously bind to three antigens on AML cells (CD33, CD123, and CD70)” PMID 38683145 ↗ Jul 2024 |
| Target | CD33 | “can simultaneously bind to three antigens on AML cells (CD33, CD123, and CD70)” PMID 38683145 ↗ Jul 2024 |
| Target | CD70 | “can simultaneously bind to three antigens on AML cells (CD33, CD123, and CD70)” PMID 38683145 ↗ Jul 2024 |